Clinical trials: GERD, Acid Reflux, Treatment
GERD
Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux Disease
The aim of this trial is to evaluate the complete remission of erosive gastroesophageal reflux disease with pantoprazole magnesium 40 mg once daily versus esomeprazole 40 mg once daily during four-week treatment with an extension…
- Trial name
- PAMES 0109 (NCT01132638)
- Testing
- Magnesium Pantoprazole, Magnesium Esomeprazole
- Where
- 9 sites in Brazil
- Volunteers
- 713 people
- Sponsor
- Takeda
Venous Reflux
VenaSeal Spectrum: Global Post-Market Randomized Controlled Trial
Global, Post-Market, Prospective, Multi-Center, Randomized Controlled Trial of the VenaSeal™ Closure System vs. Surgical Stripping or Endothermal Ablation (ETA) for the Treatment of Early and Advanced Stage Superficial Venous…
- Trial name
- NCT03820947
- Testing
- VenaSeal™ System, Endothermal Ablation (ETA), Surgical Stripping
- Where
- 32 sites in United States, Australia and 8 more
- Volunteers
- 506 people
- Sponsor
- Medtronic Endovascular
Gastroesophageal Reflux
Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)
To assess the efficacy of pantoprazole for the treatment of infants with symptomatic Gastroesophageal Reflux Disease (GERD).
- Trial name
- NCT00365300
- Testing
- pantoprazole
- Where
- 38 sites in United States
- Volunteers
- 129 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Gastroesophageal Reflux Disease, GERD
What is the Predictive Value of the Reflux Impact Scale
Gastric distress is a common phenomenon in our society. Heartburn and regurgitation occur daily in about 7% of the adult population,weekly 14-20% pf the adults and monthly in 34-44% of adults.
- Conditions
- Gastroesophageal Reflux Disease, GERD, Heartburn, Acid Regurgitation
- Trial name
- PREDICT (NCT00536328)
- Volunteers
- 938 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Diagnosis and Response to Treatment Using a Reliable Gastroesophageal Reflux Disease (GERD) Questionnaire: An In Clinical Practice Study
The purpose of the study is to determine the applicability and utility of Gerd Q in the diagnosis of GERD and in the assessment of treatment response.
- Trial name
- GQS (NCT00963144)
- Where
- 2 sites in Malaysia
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Reflux Episodes
TLESR-impedance Study in Patients
The purpose of the study is to compare frequency and content of reflux episodes in patients with gastroesophageal reflux disease.
- Trial name
- NCT00743444
- Testing
- AZD3355
- Volunteers
- 27 people
- Sponsor
- AstraZeneca
GERD
Epidemiological Study to Assess the Symptoms and Patterns of Diagnosis and Treatment of GERD
To describe the frequency, type and severity of the symptoms in patients visiting the GI or internal physicians, with symptoms consistent with gastroesophageal reflux disease (GERD)
- Trial name
- NCT00524355
- Where
- 2 sites in Vietnam
- Volunteers
- 2,717 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Study Comparing Esomeprazole Associated With Sodium Bicarbonate From Eurofarma and Esomeprazole in Treatment of Gastroesophageal Reflux Disease ESOBIC
A phase III, randomized, open-label, superiority study comparing the incremental product esomeprazole associated with sodium bicarbonate made by Eurofarma and Nexium® in the treatment of gastroesophageal reflux disease.
- Trial name
- NCT01471925
- Testing
- Nexium®, Esomeprazol (40mg) + Sodium Bicarbonate (721mg)
- Where
- 6 sites in Brazil
- Sponsor
- Eurofarma Laboratorios S.A.
Gastroesophageal Reflux Disease
Pharmacodynamic and Pharmacokinetic Study of E3710 Following Oral Administration to Healthy, Male, Japanese Subjects
The purpose of this study is to investigate the pharmacodynamics (PD) and pharmacokinetics of E3710 following oral administration to Healthy Male Japanese Subjects
- Trial name
- NCT01390714
- Testing
- E3710
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Eisai Co., Ltd.
Gastroesophageal Reflux Disease (GERD)
A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients
The purpose of the study is to access the effectiveness and safety of oral rabeprazole in the treatment of acid-related disorders in pediatric patients, focusing specifically on the manifestation of GERD (symptomatic and erosive…
- Trial name
- NCT00787891
- Testing
- rabeprazole
- Volunteers
- 127 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.